1492 Capital Management Has Boosted Its Therapeuticsmd (TXMD) Position; Widepoint (NYSEAMERICAN:WYY) Sellers Decreased By 6.25% Their Shorts

March 14, 2018 - By Peter Erickson

Widepoint Corporation (NYSEAMERICAN:WYY) had a decrease of 6.25% in short interest. WYY’s SI was 172,600 shares in March as released by FINRA. Its down 6.25% from 184,100 shares previously. With 131,900 avg volume, 1 days are for Widepoint Corporation (NYSEAMERICAN:WYY)’s short sellers to cover WYY’s short positions. The SI to Widepoint Corporation’s float is 0.28%. The stock increased 0.09% or $0.001 during the last trading session, reaching $0.542. About 190,745 shares traded or 21.34% up from the average. WidePoint Corporation (NYSEAMERICAN:WYY) has declined 44.30% since March 14, 2017 and is downtrending. It has underperformed by 61.00% the S&P500.

1492 Capital Management Llc increased Therapeuticsmd Inc (TXMD) stake by 86.42% reported in 2017Q3 SEC filing. 1492 Capital Management Llc acquired 181,115 shares as Therapeuticsmd Inc (TXMD)’s stock declined 24.96%. The 1492 Capital Management Llc holds 390,702 shares with $2.07M value, up from 209,587 last quarter. Therapeuticsmd Inc now has $1.13 billion valuation. The stock decreased 0.76% or $0.04 during the last trading session, reaching $5.24. About 1.16M shares traded. TherapeuticsMD, Inc. (NYSEMKT:TXMD) has declined 46.30% since March 14, 2017 and is downtrending. It has underperformed by 63.00% the S&P500.

Investors sentiment decreased to 1.62 in 2017 Q3. Its down 0.11, from 1.73 in 2017Q2. It dropped, as 9 investors sold TXMD shares while 28 reduced holdings. 24 funds opened positions while 40 raised stakes. 162.04 million shares or 5.51% more from 153.57 million shares in 2017Q2 were reported. Redmond Asset Mgmt Ltd Co owns 100,109 shares or 0.24% of their US portfolio. Bnp Paribas Arbitrage has 0% invested in TherapeuticsMD, Inc. (NASDAQ:TXMD). Massachusetts Financial Ser Ma holds 443,294 shares. Moreover, Rock Springs Management LP has 0.39% invested in TherapeuticsMD, Inc. (NASDAQ:TXMD). Susquehanna Intl Group Inc Limited Liability Partnership, a Pennsylvania-based fund reported 1.03 million shares. Tudor Invest Corp Et Al stated it has 0.04% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD). 84,794 are held by Us Bancshares De. Suntrust Banks Inc owns 40,703 shares for 0% of their portfolio. Alpine Woods Capital Ltd Liability reported 0% stake. Stifel stated it has 2.04M shares. Hanson Mcclain stated it has 500 shares. Manufacturers Life Insurance The owns 121,883 shares for 0% of their portfolio. Blackrock reported 0% stake. First Midwest Financial Bank Trust Division holds 0.02% or 27,800 shares in its portfolio. Aperio Grp Ltd Llc invested in 0% or 34,227 shares.

Among 4 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TherapeuticsMD had 6 analyst reports since September 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Tuesday, December 8. The rating was initiated by Oppenheimer with “Outperform” on Tuesday, November 22. On Tuesday, November 22 the stock rating was reinitiated by Jefferies with “Buy”. The stock of TherapeuticsMD, Inc. (NASDAQ:TXMD) has “Buy” rating given on Tuesday, December 8 by Stifel Nicolaus. As per Monday, September 21, the company rating was maintained by Jefferies.

WidePoint Corporation provides information technology based products, services, and solutions worldwide. The company has market cap of $45.00 million. It primarily offers communications solutions and federally certified secure identity management solutions to the government and commercial sectors through a secure proprietary portal. It currently has negative earnings. The firm provides telecom lifecycle management solutions that provide visibility of telecom assets enabling clients to secure and manage the telecom assets; and telecom analytical solutions, including bill presentment, subscriber data intelligence, and hosted voice analytics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts